Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

Author(s):

Félix Guerrero-Ramos, MD, PhD, FEBU ,Srikala Sridhar, MD

Key Takeaways

Combining BCG and PD-1/PD-L1 inhibitors may enhance antitumor activity through complementary mechanisms, potentially improving outcomes in NMIBC.
BCG stimulates immune response, while PD-1/PD-L1 inhibitors prevent immune evasion, providing a rationale for their combined use.
The combination therapy could revolutionize NMIBC treatment, particularly for high-risk patients, necessitating adjustments in patient management.
A multidisciplinary approach is crucial to optimize treatment strategies and patient care in integrating these therapies into urology practice.

Panelists discuss how combining BCG with PD-1/PD-L1 inhibitors may enhance antitumor activity compared with using each agent alone, emphasizing the rationale for this combination therapy and its potential to evolve treatment strategies for non–muscle-invasive bladder cancer (NMIBC) while also considering the implications for patient flow in urology practice and the necessity of a multidisciplinary approach.

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

Now Viewing

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP: 9.Exploring Emerging Data in NMIBC

EP: 10.Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

How might the combination of BCG and PD-1/PD-L1 inhibitors affect antitumor activity compared with using each agent alone?
What is the rationale for using these therapies in combination?
How do you think the combination therapies will evolve treatment of non–muscle-invasive bladder cancer (NMIBC)?
How would the use of PD-1/PD-L1 inhibitors plus BCG in high-risk NMIBC impact patient flow in urology practice?

THE SPEAKER WILL HIGHLIGHT THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH